Deals & Cases
MLL Legal Advises Teleflex on Swiss Law Matters in Acquisition of BIOTRONIK’s Vascular Intervention Business
The M&A and Life Sciences teams at MLL Legal AG advised Teleflex Incorporated (NYSE:TFX) on all Swiss law matters in connection with its definitive agreement to acquire substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG.
The transaction involves an estimated cash payment at closing of approximately €760 million, less certain adjustments as set forth in the purchase agreement, including certain working capital not transferring and other customary adjustments.
The acquisition is subject to customary closing conditions, including receipt of certain regulatory approvals, and is expected to be completed by the end of the third quarter of 2025.
This strategic acquisition underscores Teleflex’s commitment to investing in the $10 billion interventional cardiology and peripheral vascular market. Post-close, the acquired business will expand Teleflex’s Interventional portfolio to include a broad suite of vascular intervention devices, such as drug-coated balloons, drug-eluting stents, covered stents, balloon and self-expanding bare metal stents, and balloon catheters.
The MLL Legal AG team was led by Karin Oberlin and Mark Montanari and included Andrea Sieber, Louisa Galbraith, Renato Bucher, Thomas Kälin, Daniel Donauer, Mark-Anthony Schwestermann, Luca Henn, Andrea Heiniger, Ada Altobelli, Gabriel Privat, Munier Serag, Pranvera Rasaj, and Gianluca Bonatesta. MLL Legal worked alongside Goodwin, whose team was led by Rob Masella, Amanda Gill, Markus Käpplinger, and Adam Bellack, supported by a multidisciplinary group of professionals based in various jurisdictions.
For additional details on the acquisition, please refer to the official press release.
